Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander J Ambinder

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|January 22, 2026
Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBIMarti Goldenberg, Ravi Varadhan, Christopher J Gamper, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Blood Neoplasia|September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AMLAndrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Haematologica|August 28, 2025
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|January 22, 2026
Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBIMarti Goldenberg, Ravi Varadhan, Christopher J Gamper, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Blood Neoplasia|September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AMLAndrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Haematologica|August 28, 2025
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Pageof 2